Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice.

Jarvis, Rebecca; Josephine Ng, Shu Fun; Nathanson, Anna J; Cardarelli, Ross A; Abiraman, Krithika; Wade, Fergus; Evans-Strong, Aidan; Fernandez-Campa, Marina P et al. · Cell Rep Med · 2023

basic_science · Level V

Where this comes from

Abstract

Hyperpolarizing GABA<sub>A</sub>R currents, the unitary events that underlie synaptic inhibition, are dependent upon efficient Cl<sup>-</sup> extrusion, a process that is facilitated by the neuronal specific K<sup>+</sup>/Cl<sup>-</sup> co-transporter KCC2. Its activity is also a determinant of the anticonvulsant efficacy of the canonical GABA<sub>A</sub>R-positive allosteric: benzodiazepines (BDZs). Compromised KCC2 activity is implicated in the pathophysiology of status epilepticus (SE), a medical emergency that rapidly becomes refractory to BDZ (BDZ-RSE). Here, we have identified small molecules that directly bind to and activate KCC2, which leads to reduced neuronal Cl<sup>-</sup> accumulation and excitability. KCC2 activation does not induce any overt effects on behavior but prevents the development of and terminates ongoing BDZ-RSE. In addition, KCC2 activation reduces neuronal cell death following BDZ-RSE. Collectively, these findings demonstrate that KCC2 activation is a promising strategy to terminate BDZ-resistant seizures and limit the associated neuronal injury.

Medical subject headings